Sun Pharmaceutical Industries Ltd.

International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharmaceutical Industries and its subsidiaries or associate companies have signed an agreement for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans.

ICGEB has developed a tailored recombinant virus-like-particle (VLP) based tetravalent dengue vaccine, containing host-receptor binding domain of envelope protein of all the four DENV serotypes. ICGEB has conducted pre-clinical studies over the past seven years and developed the existing Know-How and Patents for this dengue vaccine candidate.

This is the second collaboration between Sun Pharma and ICGEB focusing on dengue. The first one announced in May 2016 was related to the development of a botanical drug for treatment of Dengue. The current collaboration is focused on developing a novel, safe & effective vaccine for the prevention of dengue.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.